Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
94.00    0.00 (0.00%)
Bid:
90.00
Ask:
98.00
Spread: 8.00 (8.889%)
Market Cap: £62.39m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Regulatory Approval

22 Jan 2018 07:00

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES UKRANIAN MARKETING AUTHORISATIONS FOR AIVLOSIN® FOR PIGS AND POULTRY

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a number of marketing authorisations for Aivlosin® from the Department for Food Safety and Veterinary from the State Service of Ukraine on Food Safety and Consumer Protection.

Aivlosin ® , ECO’s patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

These authorisations, which are for the use of Aivlosin® 625 mg/g water soluble granules and Aivlosin® 42.5 mg/g premix for both pigs and poultry, also allow ECO to start selling Aivlosin® in the Ukraine for the medication of drinking water or for mixing into feed, for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.

These new treatments meet all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, these treatments are under the control of veterinarians, available under prescription only and have low, highly effective therapeutic dose rates, a short treatment duration and a zero day or very short drug withholding period.

Peter Lawrence, Chairman of ECO, commented “We are extremely pleased to receive these marketing authorisations for Aivlosin® in the Ukraine, the sixteenth largest egg producing country and one that is ranked just outside the top twenty globally for pork production.”

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc

Peter Lawrence   020 8336 6190
Marc Loomes 020 8447 6906
Spiro Financial
Anthony Spiro 020 8336 6196
N+1 Singer (Nominated Adviser) 020 7496 3000
Mark Taylor, Brough Ransom
Peel Hunt LLP (Joint Broker)
James Steel, Dr Christopher Golden 020 7418 8900
 

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

View source version on businesswire.com: http://www.businesswire.com/news/home/20180121005079/en/

Copyright Business Wire 2018

Date   Source Headline
4th Jun 20267:00 amRNSRenewal of revolving credit facility
14th Apr 20267:00 amRNSAppointment of Head of Business Development
31st Mar 20267:00 amRNSBoard Change
19th Mar 20267:00 amRNSFull Year Trading Update
11th Mar 20267:00 amRNSECOVAXXIN® MG favourable USDA safety assessment
11th Mar 20267:00 amRNSECOVAXXIN®?MG favourable USDA safety assessment
5th Mar 20264:19 pmRNSBlock Listing Return
26th Feb 20267:00 amRNSEU launch plans for ECOVAXXIN® MS
19th Jan 20261:50 pmRNSHolding(s) in Company
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
18th Dec 20257:00 amRNSExercise of Share Options by Director
9th Dec 20255:57 pmRNSHolding(s) in Company
4th Dec 20252:10 pmRNSDirector/PDMR Shareholding
1st Dec 20257:00 amRNSResults for the six months ended 30 September 2025
20th Nov 20259:47 amRNSReplacement: Notice of Results
20th Nov 20257:00 amRNSNotice of Results
10th Nov 20257:00 amRNSEMA Positive Opinion Received for ECOVAXXIN® MS
1st Oct 20257:00 amRNS-RHead of Global R&D
25th Sep 20253:15 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Trading Update and Notice of Interim Results
1st Sep 20257:00 amRNSAppointment of Joint Broker
29th Aug 20257:00 amRNSShare Awards to Executive Directors
28th Aug 20257:48 amRNSPosting of Annual Report and Notice of AGM
21st Aug 202512:29 pmRNSResult of General Meeting
13th Aug 20257:00 amRNSBlock Listing Return
6th Aug 20255:09 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSResults for the year ended 31 March 2025
8th Jul 20254:10 pmRNSNotice of General Meeting and Notice of Results
2nd May 20257:00 amRNSHolding(s) in Company
28th Apr 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSTrading Update
13th Mar 20257:00 amRNSR&D Day
3rd Mar 20257:00 amRNSSubmission of Marketing Authorisation Application
24th Feb 20254:08 pmRNSHolding(s) in Company
19th Feb 20257:00 amRNSDisposal of non-core assets
18th Feb 20257:00 amRNSBlock listing Interim Review
13th Feb 20257:00 amRNSNotice of R&D Day
31st Jan 20257:00 amRNSBoard Changes
20th Dec 20247:00 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSHolding(s) in Company
2nd Dec 202412:30 pmRNSShare Purchase by Executive Director
28th Nov 20247:00 amRNSResults for the Six Months Ended 30 September 2024
28th Oct 202412:57 pmRNSShare Awards to Executive Directors
22nd Oct 202411:00 amRNSEBT Share Purchase
21st Oct 20247:00 amRNSEBT Share Purchase
14th Oct 202411:07 amRNSEBT Share Purchase
9th Oct 20247:00 amRNSIssue of Equity and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.